BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Response to oxidative stress
,
Arthritis
,
Stem cell
,
Biofuel
,
Valproic acid
,
rs2300478
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
di 3
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Iron chelation in regulation of gene expression in DMS-53 small cell lung carcinoma cells
Assessment of ex vivo prostaglandin pathway activation in hematopoietic stem cells
Explore Curated Studies Results
Literature
Most Relevant Literature
DIS3: The Enigmatic Gene in Multiple Myeloma.
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centr…
Epididymal DIS3 exosome ribonuclease is not necessary for mouse sperm maturation or fertility.
DIS3 Variants are Associated With Primary Ovarian Insufficiency: Importance of Transcription/Transla…
RNA exosome ribonuclease DIS3 degrades Pou6f1 to promote mouse pre-implantation cell differentiation…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pharmacokinetics of C6 Ketone Di-ester
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients…
A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ